Synlogic_Logo_Blue.png
Synlogic Announces Contract with the Air Force Research Lab
27. Dezember 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
07. Dezember 2023 07:00 ET | Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...
Synlogic_Logo_Blue.png
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
07. November 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
03. Oktober 2023 16:15 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
29. September 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
11. Juli 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
28. Juni 2023 07:00 ET | Synlogic, Inc.
The World Health Organization has approved “labafenogene marselecobac”Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria communityCAMBRIDGE, Mass., June...
iBio Receives US and European Patents for Protein Expression Technology
12. Februar 2015 08:31 ET | iBio, Inc.
NEWARK, DE--(Marketwired - Feb 12, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issuance of...
iBio Adds to iBioModulator Portfolio and Product Pipeline
04. Februar 2015 08:31 ET | iBio, Inc.
NEWARK, DE--(Marketwired - Feb 4, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issue of a new...
iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
10. Dezember 2014 08:31 ET | iBio, Inc.
NEWARK, DE--(Marketwired - Dec 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and...